Scottish consensus statement on the role of FeNO in adult asthma

Chris Ruiwen Kuo, Mark Spears, John Haughney, Andrew Smith, Joy Miller, Tracey Bradshaw, Lorna Murray, Peter Williamson, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)
32 Downloads (Pure)

Abstract

Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalRespiratory Medicine
Volume155
Early online date6 Jul 2019
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Asthma
  • FeNO
  • Type 2 Inflammation

Fingerprint Dive into the research topics of 'Scottish consensus statement on the role of FeNO in adult asthma'. Together they form a unique fingerprint.

Cite this